A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Sun Pharma’s head of biologics marketing Maureen Shannon said, “We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...